DUBLIN — February 26, 2018 — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved a new arm indication for the Guardian(TM) Sensor 3.

INDIANAPOLIS, Feb. 26, 2018 — Trulicity® (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, according to results from AWARD-10, a new Phase 3b clinical study. These data were published online first in The Lancet Diabetes & Endocrinology.

Night shift work is associated with a higher risk of developing type 2 diabetes, regardless of genetic risk, according to a new study published in Diabetes Care.

San Francisco-based startup PlateJoy, a personalized meal-planning company, will add weight tracking and virtual coaching to its services to treat individuals with prediabetes.

Public health experts and art educators have teamed up to prevent youth from succumbing to diabetes by conducting workshops in low socio-economic communities to educate high-risk populations about diabetes.

American Heart Association CEO Nancy Brown applauded McDonald’s leadership in ensuring kids’ meals at the fast food giant will offer more fruits, vegetables, whole grains water and low-fat dairy for “millions of families globally” as part of a long-term global growth plan.

For older patients with heart failure with preserved ejection fraction (HFpEF), systolic blood pressure (SBP) levels below 120 mm Hg—and even 130—are associated with worse short- and long-term cardiovascular outcomes, according to a study published online Feb. 14 in JAMA Cardiology.

Researchers have identified a gene, called MeXis, that helps remove cholesterol from blood vessels. Senior study author Peter Tontonoz, MD, PhD, and colleagues found mice lacking MeXis had nearly twice as many blockages in their blood vessels as those that had normal levels of the gene.